EUVIMEDEUVIMED entdecken
Fallbericht

Back to normal: super-response to mavacamten in a patient with obstructive hypertrophic cardiomyopathy

Tobia Albertini, Alain M Bernheim, Annina A Studer Bruengger

The International Journal of Cardiovascular Imaging · 2025

DOI: 10.1007/s10554-025-03452-4 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The International Journal of Cardiovascular Imaging, 2025. Verfasst von Tobia Albertini und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Stadtspital Zürich, Zurich, Switzerland. tobia.albertini@gmail.com. Hauptthemen laut MEDLINE: Mitral Valve Insufficiency, Ventricular Outflow Obstruction, Cardiomyopathy, Hypertrophic, Ventricular Function, Left. Die Arbeit nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder characterized by left ventricular hypertrophy, often leading to left ventricular outflow tract (LVOT) obstruction and secondary mitral regurgitation (MR) due to systolic anterior motion (SAM) of the mitral valve leaflets. Mavacamten, a cardiac myosin inhibitor, is a modern treatment option aimed at reducing myocardial contractility, SAM and LVOT obstruction. We present the case of a patient with HCM responding not only with a marked reduction in LVOT obstruction and mitral regurgitation, but also with normalization of left ventricular (LV) mass.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mitral Valve InsufficiencyVentricular Outflow ObstructionCardiomyopathy, HypertrophicVentricular Function, LeftCardiovascular AgentsHumansTreatment OutcomeMaleMiddle AgedRecovery of FunctionMyocardial ContractionEchocardiography, Doppler, ColorBenzylaminesUracil

Stichwörter der Autor:innen

Hypertrophic cardiomyopathy with left ventricular outflow tract obstructionMavacamtenMitral valve systolic anterior motionMyosin inhibitor

Substanzen

Cardiovascular AgentsMYK-461BenzylaminesUracil

Autor:innen und Institutionen

  • Department of Cardiology, Stadtspital Zürich, Zurich, Switzerland. tobia.albertini@gmail.com.
  • Cardiology Resident, Stadtspital Zürich, Zürich, Switzerland. tobia.albertini@gmail.com.
  • Department of Cardiology, Stadtspital Zürich, Zurich, Switzerland.
  • Institute for Radiology and Nuclear Medicine, Stadtspital Zürich, Zurich, Switzerland.

Zitieren

APA

Albertini, T., Bernheim, A. M., & Bruengger, A. A. S. (2025). Back to normal: super-response to mavacamten in a patient with obstructive hypertrophic cardiomyopathy. The International Journal of Cardiovascular Imaging. https://doi.org/10.1007/s10554-025-03452-4

Vancouver

Albertini T, Bernheim AM, Bruengger AAS. Back to normal: super-response to mavacamten in a patient with obstructive hypertrophic cardiomyopathy. The International Journal of Cardiovascular Imaging. 2025. doi:10.1007/s10554-025-03452-4

BibTeX
@article{Albertini2025,
  author = {Albertini, Tobia and Bernheim, Alain M and Bruengger, Annina A Studer},
  title = {Back to normal: super-response to mavacamten in a patient with obstructive hypertrophic cardiomyopathy},
  journal = {The International Journal of Cardiovascular Imaging},
  year = {2025},
  doi = {10.1007/s10554-025-03452-4}
}
Kostenlos starten →